News

Stocktwits on MSN1h
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare
Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is ...
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Why Novo Nordisk Stock Crumbled Again Today
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk Stock Drops Further on Bank of America Downgrade
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
Stock Movers: Novo Nordisk, Palo Alto, Union Pacific
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Novo Nordisk Shares Plummet as Competition Weighs on Sales
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...